- Home
- SCD vs GALT Comparison
SCD vs GALT Comparison
Compare SCD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCD | GALT |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.8M | 397.3M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | SCD | GALT |
|---|---|---|
| Price | $15.40 | $3.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 61.4K | ★ 197.8K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.79 | $2.03 |
| 52 Week High | $16.18 | $7.13 |
Technical Indicators
Market Signals| Indicator | SCD | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 45.90 |
| Support Level | $15.11 | $2.71 |
| Resistance Level | $15.52 | $3.56 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 84.06 | 42.46 |
Price Performance
Historical ComparisonAbout SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.